The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Early Changes in Biochemical Markers of Bone Turnover Predict the Long-Term Response to Alendronate Therapy in Representative Elderly Women: A Randomized Clinical Trial
Abstract
Although the antiresorptive agent alendronate has been shown to increase bone mineral density (BMD) at the hip and spine and decrease the incidence of osteoporotic fractures in older women, few data are available regarding early prediction of long-term response to therapy, particularly with regard to increases in hip BMD. Examining short-term changes in biochemical markers incorporates physiologic response with therapeutic compliance and should provide useful prognostic information for patients. The objective of this study was to examine whether early changes in biochemical markers of bone turnover predict long-term changes in hip BMD in elderly women. The study was a double-blind, placebo-controlled, randomized clinical trial which took place in a community-based academic hospital. One hundred and twenty community-dwelling, ambulatory women 65 years of age and older participated in the study. Intervention consisted of alendronate versus placebo for 2.5 years. All patients received appropriate calcium and vitamin D supplementation. The principal outcome measures included BMD of the hip (total hip, femoral neck, trochanter, and intertrochanter), spine (posteroanterior [PA] and lateral), total body, and radius. Biochemical markers of bone resorption included urinary N-telopeptide cross-linked collagen type I and free deoxypyridinoline; markers of bone formation included serum osteocalcin and bone-specific alkaline phosphatase. Long-term alendronate therapy was associated with increased BMD at the total hip (4.0%), femoral neck (3.1%), trochanter (5.5%), intertrochanter (3.8%), PA spine (7.8%), lateral spine (10.6%), total body (2.2%), and one-third distal radius (1.3%) in elderly women (all p < 0.01). In the placebo group, bone density increased 1.9–2.1% at the spine (p < 0.05) and remained stable at all other sites. At 6 months, there were significant decreases in all markers of bone turnover (–10% to –53%, p < 0.01) in women on alendronate. The changes in urinary cross-linked collagen at 6 months correlated with long-term bone density changes at the hip (r = –0.35, p < 0.01), trochanter (r = –0.36, p < 0.01), PA spine (r = –0.41, p < 0.01), and total body (r = –0.34, p < 0.05). At 6 months, patients with the greatest drop in urinary cross-linked collagen (65% or more) demonstrated the greatest gains in total hip, trochanteric, and vertebral bone density (all p < 0.05). A 30% decrease in urinary cross-linked collagen at 6 months predicted a bone density increase of 2.8–4.1% for the hip regions and 5.8–6.9% for the spine views at the 2.5-year time point (p < 0.05). There were no substantive associations between changes in biochemical markers and bone density in the placebo group. Alendronate therapy was associated with significant long-term gains in BMD at all clinically relevant sites, including the hip, in elderly women. Moreover, these improvements were associated with early decreases in biochemical markers of bone turnover. Early dynamic decreases in urinary cross-linked collagen can be used to monitor and predict long-term response to bisphosphonate therapy in elderly women. Future studies are needed to determine if early assessment improves long-term patient compliance or uncovers poor compliance, thereby aiding the physician in maximizing the benefits of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bone density at various sites for prediction of hip fractures
Cummings, S. R., Browner, W., Cummings, S. R., Black, D. M., Nevitt, M. C., Browner, W., Genant, H. K., Cauley, J., Ensrud, K., Scott, J., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)92555-8 · Cited by 2,446
A Model of Lifetime Osteoporosis Impact
Chrischilles, E. A. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400100100017 · Cited by 467
Cited by
Papaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A., Jamal, S. A., Kaiser, S. M., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,749
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
Peacock, M., Turner, C. H., Econs, M. J., & Foroud, T. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0464 · Cited by 468
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001155.pub2 · Cited by 401
Kurland, E. S., Cosman, F., McMahon, D. J., Rosen, C. J., Lindsay, R., & Bilezikian, J. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6818 · Cited by 360
Metadata
- Authors
- Greenspan, S. L., Parker, R. A., Ferguson, L., Rosen, H. N., Maitland-Ramsey, L., & Karpf, D. B.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-09-01
- Volume
- 13
- Issue
- 9
- Pages
- 1431-1438
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1968198917
- Cited by
- 238
- References
- 2
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early Changes in Biochemical Markers of Bone Turnover Predict the Long-Term Response to Alendronate Therapy in Representative Elderly Women: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1359/jbmr.1998.13.9.1431
- The paper
- Greenspan, S. L., Parker, R. A., Ferguson, L., Rosen, H. N., Maitland-Ramsey, L., & Karpf, D. B. (1998). Early Changes in Biochemical Markers of Bone Turnover Predict the Long-Term Response to Alendronate Therapy in Representative Elderly Women: A Randomized Clinical Trial. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.1998.13.9.1431
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.